Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The company has seen success in animal studies and human pilot studies, but setbacks may occur in advanced clinical trials. This change might result in significant impacts on future valuations.
- The company may face challenges retaining qualified personnel, which could impair commercialization efforts and lead to negative pricing pressure on technology.
- The company may not secure patents for some applications, impacting the ability to develop DehydraTECH and potentially reducing future revenues.
- The company may conduct clinical trials outside the U.S., which could affect acceptance of study data by regulatory authorities.
- Awareness of personal data breaches and cyber security threats is at an all-time high, potentially impacting business reputation and competitive position.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1348362&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.